Denmark's Novo Nordisk debuts Victoza in the USA, aiming for $1 billion global sales by 2015
Denmark's Novo Nordisk, the world's largest insulin maker, yesterday announced that its diabetes drug Victoza (liraglutide [rDNA origin] injection) is now available in the USA, just three weeks after gaining approval from the Food and Drug Administration (The Pharma Letter January 26).
Victoza is the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. The cost of the drug in the USA is about $240/month for the 1.2mg treatment dose and $360/month for the 1.8mg dose, the company told The Pharma Letter.
Novo Nordisk expects Victoza to generate $1 billion in sales globally by 2015 with North America being a major driver, a spokeswoman told TPL. 'Last year, North America accounted for 36% of overall NN sales and led the company's growth driving almost half (48%) of its15% growth,' she added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze